PTEN loss is not a determinant of time to castration-resistance following androgen-deprivation therapy in prostate cancer: a study from Jordan

Alzoubi Abdallah 1 2 et al.
2023
Issue 4
pp 593 - 598
DOI: 10.25122/jml-2023-0034

Androgen deprivation therapy (ADT) remains the principal treatment of advanced prostate cancer. However, most patients eventually experience treatment failure, resulting in castrate-resistant prostate cancer (CRPC). Loss of the...

View Article Download PDF